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Abstract
The ‘cancer stem cell hypothesis’ posits that cancers, including
breast cancer, arise in tissue stem or progenitor cells. If this is the
case, then it follows that the risk for developing breast cancer may
be determined in part by the number of breast stem/progenitor
cells that can serve as targets for transformation. Stem cell number
may be set during critical windows of development, including in
utero, adolescence, and pregnancy. The growth hormone/insulin-
like growth factor-1 axis may play an important role in regulating
breast stem cell number during these developmental windows,
suggesting an important link between this signaling pathway and
breast cancer risk.
In the previous issue of the journal, Savareses and coworkers
[1] propose that there is a relationship between breast stem
cell number in utero and subsequent risk for breast cancer
development. They also suggest that assessing the number
of hematopoietic stem/progenitor cells may provide a
surrogate measure of this risk.
Recent evidence has provided support for the ‘cancer stem
cell hypothesis’, which holds that cancers originate in tissue,
stem, or progenitor cells; hence, carcinogenesis is driven by a
small group of cells that retain stem cell properties [2]. These
properties include self-renewal as well as differentiation. It
follows that the risk for cancer development might be directly
related to the size of the stem cell pool and its mitotic activity.
Development of the mammary gland in both humans and
rodents is regulated at three critical stages of development:
during embryogenesis, puberty, and pregnancy. During
embryonic development a rudimentary mammary gland is
formed under the influence of maternal and placental
hormones. Full mammary development is achieved during
puberty, with further morphogenetic modifications occurring
during pregnancy, lactation, and involution. Changes in the
hormonal milieu during each of these stages of development
may regulate the size of the breast stem cell pool, and so they
may influence the development of carcinogenesis.
Both epidemiologic and experimental evidence has suppor-
ted the hypothesis that the in utero environment influences
cancer risk in offspring later in life. A number of studies have
demonstrated a strong link between birth weight and breast
cancer risk in offspring, as well as a strong association of
maternal levels of insulin-like growth factor (IGF)-1 and birth
weight [3]. This has led to the hypothesis, first articulated by
Trichocopulous [4], that levels of hormones such as IGF-1
and steroid hormones in utero may influence subsequent
breast cancer risk by regulating the number of mammary stem
cells. Indirect support for this stem cell based hypothesis was
provided in a pilot study of 40 umbilical cord blood samples,
which demonstrated a strong positive link between maternal
levels of IGF-1 and steroid hormones and the number of
hematopoietic stem cells in cord blood.
The study conducted by Savarese and coworkers [1]
reported in this journal confirms and extends these studies by
demonstrating a strong correlation of cord blood plasma
levels of both IGF-1 and estradiol with the number of
hematopoietic stem and progenitor cells. Because previous
studies have demonstrated a strong link of both birth weight
and IGF-1 levels in utero with subsequent risk for breast
cancer, the authors propose that this link occurs through
regulation of breast stem cell numbers by these hormones.
This conclusion is based on the assumption that common
mechanisms regulate the number of hematopoietic and
breast stem cells.
Although no direct evidence for such linkage is provided in
the report or elsewhere, it is plausible to posit common
regulatory mechanisms for adult stem cells in different
tissues. Indeed, there is evidence that the growth hormone/
IGF-1 axis may serve as a master regulator, coordinating stem
cell numbers in multiple organs. Growth hormone is an
anabolic pulsatile hormone that is secreted by the pituitary
gland. Growth hormone is the major regulator of IGF-1
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synthesis and secretion by the liver as well as by peripheral
tissues. In addition to the indirect effects of growth hormone
on cell proliferation mediated by IGF-1, it also acts directly on
cells that express the growth hormone receptor through
stimulation of JAK/STAT (Janus kinase/signal transducer and
activator of transcription) pathway signaling [5]. Furthermore,
recent evidence suggests a role for growth hormone in
regulation of the hematopoietic system [6]. Interestingly, we
previously reported that growth hormone receptor is over-
expressed in human mammary epithelial stem/progenitor cells
grown in mammospheres as compared with cells induced to
differentiate by attachment to a collagen substratum [7].
The role played by growth hormone in mammary development
is demonstrated by the rudimentary breast development seen
in growth hormone receptor knockout mice [8] and by the
observation that acromegalic patients who have increased
growth hormone levels exhibit increased risk for cancers,
including breast cancer [9]. Furthermore, it has recently been
demonstrated that breast cancer risk correlates strongly with
height at puberty, a characteristic that is strongly correlated
with growth hormone levels [10]. In addition to growth
hormone secretion by the pituitary gland, there is evidence for
production of growth hormone by differentiated mammary
epithelial cells in dogs, rats, and women [11]. Furthermore,
this local growth hormone production is regulated by high
levels of progesterone, which occur during pregnancy. Breast
tissue growth hormone production may thus contribute to the
high levels of this hormone observed during the third
trimester of pregnancy.
The report by Servarese and coworkers [1], together with
other epidemiologic studies, suggests a unifying hypothesis
for breast cancer risk related to stem cell number, which is
regulated by the growth hormone/IGF-1 axis. This signaling
network may play a role in regulating mammary stem cell
number and proliferation during key windows of mammary
development, including in utero, adolescence, and
pregnancy. Furthermore, if breast cancers originate in
mammary stem/progenitor cells, then it follows that inter-
ventions aimed at regulating mammary stem cell number or
proliferation represent a rational strategy for breast cancer
prevention.
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